在阿尔茨海默病中，RAGE是β淀粉样蛋白诱导的细胞功能紊乱的关键细胞靶点。
RAGE is a key cellular target for Abeta-induced perturbation in Alzheimer's disease.
作者信息
Yan Shirley ShiDu, Chen Doris, Yan Shiqian, Guo Lan, Du Heng, Chen John Xi
机构信息
Department of Surgery, Physicians and Surgeons College of Columbia University, New York, NY 10032, USA.
出版信息
Front Biosci (Schol Ed). 2012 Jan 1;4(1):240-50. doi: 10.2741/s265.
Abstract
RAGE, a receptor for advanced glycation endproducts, is an immunoglobulin-like cell surface receptor that is often described as a pattern recognition receptor due to the structural heterogeneity of its ligand. RAGE is an important cellular cofactor for amyloid beta-peptide (Abeta)-mediated cellular perturbation relevant to the pathogenesis of Alzheimer's disease (AD). The interaction of RAGE with Abeta in neurons, microglia, and vascular cells accelerates and amplifies deleterious effects on neuronal and synaptic function. RAGE-dependent signaling contributes to Abeta-mediated amyloid pathology and cognitive dysfunction observed in the AD mouse model. Blockade of RAGE significantly attenuates neuronal and synaptic injury. In this review, we summarize the role of RAGE in the pathogenesis of AD, specifically in Abeta-induced cellular perturbation.
摘要
晚期糖基化终产物受体（RAGE）是一种免疫球蛋白样细胞表面受体，由于其配体的结构异质性，它常被描述为一种模式识别受体。RAGE是淀粉样β肽（Aβ）介导的与阿尔茨海默病（AD）发病机制相关的细胞扰动的重要细胞辅因子。RAGE与神经元、小胶质细胞和血管细胞中的Aβ相互作用，加速并放大了对神经元和突触功能的有害影响。在AD小鼠模型中观察到，RAGE依赖性信号传导促成了Aβ介导的淀粉样病理和认知功能障碍。阻断RAGE可显著减轻神经元和突触损伤。在本综述中，我们总结了RAGE在AD发病机制中的作用，特别是在Aβ诱导的细胞扰动中的作用。
相似文献
1
RAGE is a key cellular target for Abeta-induced perturbation in Alzheimer's disease.
Front Biosci (Schol Ed). 2012 Jan 1;4(1):240-50. doi: 10.2741/s265.
2
RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease.
Curr Mol Med. 2007 Dec;7(8):735-42. doi: 10.2174/156652407783220741.
3
RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease.
FASEB J. 2010 Apr;24(4):1043-55. doi: 10.1096/fj.09-139634. Epub 2009 Nov 11.
4
Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease.
Curr Drug Targets CNS Neurol Disord. 2005 Jun;4(3):249-66. doi: 10.2174/1568007054038210.
5
RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation?
J Alzheimers Dis. 2009;16(4):833-43. doi: 10.3233/JAD-2009-1030.
6
Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism.
Exp Neurol. 2001 Sep;171(1):29-45. doi: 10.1006/exnr.2001.7732.
7
Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity.
J Neurosci. 2008 May 14;28(20):5149-58. doi: 10.1523/JNEUROSCI.4878-07.2008.
8
Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease.
Brain Res. 2001 Jan 12;888(2):256-262. doi: 10.1016/s0006-8993(00)03075-4.
9
Crosstalk between calcium, amyloid beta and the receptor for advanced glycation endproducts in Alzheimer's disease.
Rev Neurosci. 2009;20(2):95-110. doi: 10.1515/revneuro.2009.20.2.95.
10
RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice.
EMBO J. 2004 Oct 13;23(20):4096-105. doi: 10.1038/sj.emboj.7600415. Epub 2004 Sep 30.
引用本文的文献
1
A systematic review on type 3 diabetes: bridging the gap between metabolic dysfunction and Alzheimer's disease.
Diabetol Metab Syndr. 2025 Aug 27;17(1):356. doi: 10.1186/s13098-025-01930-2.
2
Amyloid β-Induced Inflammarafts in Alzheimer's Disease.
Int J Mol Sci. 2025 May 10;26(10):4592. doi: 10.3390/ijms26104592.
3
Tailoring MAPK Pathways: New Therapeutic Avenues for Treating Alzheimer's Disease.
Mol Neurobiol. 2025 Apr 21. doi: 10.1007/s12035-025-04919-0.
4
Murine Non-Transgenic Models of Alzheimer's Disease Pathology: Focus on Risk Factors.
Brain Sci. 2025 Mar 19;15(3):322. doi: 10.3390/brainsci15030322.
5
Pathological role of RAGE underlying progression of various diseases: its potential as biomarker and therapeutic target.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr;398(4):3467-3487. doi: 10.1007/s00210-024-03595-6. Epub 2024 Nov 26.
6
Multiple Roles of Apolipoprotein E4 in Oxidative Lipid Metabolism and Ferroptosis During the Pathogenesis of Alzheimer's Disease.
J Mol Neurosci. 2024 Jul 3;74(3):62. doi: 10.1007/s12031-024-02224-4.
7
Inhibition of Amyloid-β (Aβ)-Induced Cognitive Impairment and Neuroinflammation in CHI3L1 Knockout Mice through Downregulation of ERK-PTX3 Pathway.
Int J Mol Sci. 2024 May 19;25(10):5550. doi: 10.3390/ijms25105550.
8
and Genes Transporting Amyloid and Tau Protein in the Hippocampal CA3 Area in an Ischemic Model of Alzheimer's Disease with 2-Year Survival.
Cells. 2023 Dec 4;12(23):2763. doi: 10.3390/cells12232763.
9
Aβ42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer's disease brain extracts.
Alzheimers Res Ther. 2022 Dec 29;14(1):196. doi: 10.1186/s13195-022-01141-1.
10
Pathophysiology of RAGE in inflammatory diseases.
Front Immunol. 2022 Jul 29;13:931473. doi: 10.3389/fimmu.2022.931473. eCollection 2022.
本文引用的文献
1
Structural basis for ligand recognition and activation of RAGE.
Structure. 2010 Oct 13;18(10):1342-52. doi: 10.1016/j.str.2010.05.017.
2
The 1.5 Å crystal structure of human receptor for advanced glycation endproducts (RAGE) ectodomains reveals unique features determining ligand binding.
J Biol Chem. 2010 Dec 24;285(52):40762-70. doi: 10.1074/jbc.M110.169276. Epub 2010 Oct 13.
3
Microglial receptor for advanced glycation end product-dependent signal pathway drives beta-amyloid-induced synaptic depression and long-term depression impairment in entorhinal cortex.
J Neurosci. 2010 Aug 25;30(34):11414-25. doi: 10.1523/JNEUROSCI.2127-10.2010.
4
The S100B/RAGE Axis in Alzheimer's Disease.
Cardiovasc Psychiatry Neurol. 2010;2010:539581. doi: 10.1155/2010/539581. Epub 2010 Jun 21.
5
AGEs/RAGE complex upregulates BACE1 via NF-κB pathway activation.
Neurobiol Aging. 2012 Jan;33(1):196.e13-27. doi: 10.1016/j.neurobiolaging.2010.05.026. Epub 2010 Jul 17.
6
Oxidative stress mediates the pathogenic effect of different Alzheimer's disease risk factors.
Front Aging Neurosci. 2010 Feb 9;2:3. doi: 10.3389/neuro.24.003.2010. eCollection 2010.
7
Role of mitochondrial amyloid-beta in Alzheimer's disease.
J Alzheimers Dis. 2010;20 Suppl 2:S569-78. doi: 10.3233/JAD-2010-100357.
8
RAGE does not affect amyloid pathology in transgenic ArcAbeta mice.
Neurodegener Dis. 2009;6(5-6):270-80. doi: 10.1159/000261723. Epub 2010 Feb 10.
9
RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease.
FASEB J. 2010 Apr;24(4):1043-55. doi: 10.1096/fj.09-139634. Epub 2009 Nov 11.
10
Association between the RAGE G82S polymorphism and Alzheimer's disease.
J Neural Transm (Vienna). 2010 Jan;117(1):97-104. doi: 10.1007/s00702-009-0334-6. Epub 2009 Nov 10.
Zotero 插件